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The matrix (MA) proteins of human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) are
known to be important for the targeting and assembly of lentiviral proteins. The objective of the present study was to
determine whether the MA protein of HIV-1 was sufficient for particle assembly and release. Eukaryotic expression of
wild-type HIV-1 Gag-Pol, HIV-1 MA alone, or SIV MA alone was analyzed with radio-immunoprecipitation, density centrifu-
gation, and a protease protection assay. Cells that expressed HIV-1 Gag-Pol or SIV MA alone released virus-like particles
(VLPs) with sucrose gradient densities of 1.15 or 1.12 g/ml, respectively. The MA and/or capsid proteins in these particles
were protected from protease degradation, indicating the presence of a protective outer membrane. Expression of HIV-1 MA
protein alone resulted in release of MA which pelleted through a 20% sucrose cushion but failed to enter a 20–60% sucrose
gradient and was not protected from protease degradation. The MA protein of SIV was previously reported to be sufficient
for production of VLPs (S. A. Gonzalez, H, K, Affrachino, H. R. Gelderblom, and A. Burney. Virology 194, 548–556, 1993; V. Liska,
D. Spehner, M. Mehtali, D. Schmitt, A. Kirn, and A. M. Aubertin. J. Gen. Virol. 75, 2955–2962, 1994). Our study confirmed that
result, but indicated that the MA protein of HIV-1 was not sufficient to assemble and release VLPs. © 1998 Academic Press
INTRODUCTION
HIV-1 and SIV are lentiviruses that utilize a type-C-like
retroviral strategy for morphogenesis. The precise mo-
lecular mechanisms that achieve virion assembly, bud-
ding, and maturation are still largely unknown. As with
other oncoviruses and lentiviruses, the HIV-1 and SIV
Gag polyproteins in the absence of other viral proteins
are sufficient for the assembly and budding of VLPs
(Gheysen et al., 1989; Shioda and Shibuta, 1990; Wills
and Craven, 1991) However, several other viral mole-
cules, including glycoproteins, enzymes, and RNA, are
required for the production of infectious particles. HIV-1
and SIV Gag polyproteins assemble into immature viri-
ons during budding and are subsequently cleaved by the
viral protease to produce mature virions containing the
processed Gag subunit proteins: matrix (MA), capsid
(CA), nucleocapsid (NC), and p6 (Henderson et al., 1998;
Mervis et al., 1988).
The HIV-1 MA protein is modified by the addition of a
myristic acid moiety at an N-terminal glycine. It has been
shown that this modification plus other downstream se-
quences are responsible for the targeting of MA to the
plasma membrane (Bryant and Ratner, 1990; Freed et al.,
1994; Lee and Linial, 1994; Spearman et al., 1994; Zhou et
al., 1994). Mutations in the HIV-1 MA protein can redirect
particle formation to internal cellular compartments
(Facke et al., 1993; Freed et al., 1994; Gallina et al., 1994;
Chazal et al., 1995). MA also contains a nuclear localiza-
tion signal which targets the viral preintegration complex
to the nucleus after viral penetration (Bukrinsky et al.,
1993). In addition, HIV-1 MA was shown to be responsi-
ble for the specific incorporation of viral glycoproteins
into viral particles (Yu et al., 1992; Facke et al., 1993;
Wang et al., 1993; Lee and Linial, 1994).
Regions within the central and C-terminal portions of
HIV-1 MA were shown to be important for efficient par-
ticle assembly and release (Freed et al., 1994; Wagner et
al., 1994; Chazal et al., 1995). In an MuLV system, it was
shown that wild-type MuLV Gag could coassemble with
a chimeric Gag containing either heterologous MA or
heterologous CA, suggesting that either protein could
mediate Gag–Gag interactions necessary for particle
production (Deminie and Emerman, 1993). It was re-
ported that MA protein of SIV of sooty mangabeys
(SIVsmm), in the absence of other viral molecules, was
sufficient to direct the release of VLPs (Gonzalez et al.,
1993; Liska et al., 1994).
We hypothesized that HIV-1 MA, independent of all
other viral proteins, would be capable of directing the
protein–protein interactions necessary for the assembly
and release of VLPs. We expressed HIV-1 Gag-Pol, HIV-1
MA alone, or SIV MA alone, in a eukaryotic expression
system. Using metabolic labeling of recombinant pro-
teins, sucrose density gradients, and a protease protec-
tion assay, we found that HIV-1 MA alone was incapable
of forming VLPs. Interestingly, employing these same
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methodologies, we confirmed that SIV MA was sufficient
for the assembly and release of VLPs.
RESULTS
Recombinant HIV-1 MA protein was released from
cells and pelleted through a 20% sucrose cushion
To confirm recombinant protein expression, the re-
combinant vaccina vectors, V V:gag (HIV-1), rVVmatrix
(HIV-1), or rV V/SC11, were inoculated onto H9 cells,
and the cultures were metabolically labeled with 3H-
leucine overnight. Cell lysate supernatants or lysed
viral pellets were immunoprecipitated and separated
by SDS–PAGE. In the cell lysate supernatants from VV:
gag (HIV-1) infected cells, we detected the Gag polypro-
tein (p55), the p41 processing intermediate, and the ma-
ture products, p24 capsid (CA) and p17 matrix (MA)
(Fig. 1). In the cell lysate supernatant of cells infected
with the rVVmatrix (HIV-1) construct, high levels of a
17-kDa protein consistent with MA were observed. In the
pellets derived from the culture media of VV:gag (HIV-1)
infected cells, predominantly CA was detected but MA
was also observed. The pellets from the rVVmatrix
(HIV-1) construct contained the 17-kDa immunoreactive
protein corresponding to MA.
In other experiments, 3H-myristic acid was employed
for metabolic labeling. For VV:gag (HIV-1), the Gag
polyprotein, the p41 intermediate, and the 17-kDa MA
protein were myristylated and, as expected, CA was not
(Fig. 2). For rVVmatrix (HIV-1), the 17-kDa MA protein was
myristylated. These results indicated that VV:gag (HIV-1)
and rVVmatrix (HIV-1) expressed posttranslationally
modified HIV-1 Gag or MA proteins with the expected
electrophoretic mobilities. Furthermore, these recombi-
nant HIV-1 Gag or MA proteins were released into media
and pelleted through a sucrose cushion.
We also wished to analyze and confirm SIV MA alone
assembly using the same methodologies we were ap-
plying to HIV-1 MA alone. CV-1 cells were infected with
rVVp17 (SIV) and labeled with 3H-leucine to demonstrate
SIV MA expression. A 16- to 17-kDa protein was ob-
served in both the cell lysate supernatant and in the
culture medium (data not shown).
The released HIV-1 MA protein failed to enter a
sucrose density gradient
To determine whether the MA proteins that were ex-
pressed by rVVmatrix (HIV-1) or rVVp17 (SIV) assembled
into VLPs, density gradient centrifugation was employed.
H9 cells were infected with rVVmatrix (HIV-1), VV:gag
FIG. 2. Autoradiograph demonstrating myristic acid labeled HIV-1
Gag and MA proteins. H9 cells infected with the rV Vs were labeled
overnight with 3H-myristic acid. The cells were lysed and immunopre-
cipitated followed by SDS–PAGE and autoradiography. Control vac-
cinia, C; rV Vmatrix (HIV-1), M; or V V:gag (HIV-1), G.
FIG. 1. Autoradiograph demonstrating leucine-labeled recombinant
HIV-1 MA proteins both in cells and pellet fractions. H9 cells were
infected with the control vaccinia virus (C), rV Vmatrix (HIV-1) (M), or
V V:gag (HIV-1) (G). The infected cells were leucine starved and then
labeled overnight with 3H-leucine. The media were layered over a
sucrose cushion and pelleted by ultracentrifugation. The pellets or cells
were lysed and immunoprecipitated followed by SDS–PAGE and auto-
radiography.
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(HIV-1), or control. CV-1 cells were infected with rVVp17
(SIV) or VV:gag (HIV-1). After an overnight labeling pe-
riod, the media were filtered, layered over a 20–60%
sucrose gradient, and centrifuged. For VV:gag (HIV-1)
infection of H9 cells, MA and CA migrated into the gra-
dient and were localized to fractions 8–12 (Fig. 3a). The
average of the measured densities of these fractions
was 1.15 g/ml, similar to that reported for HIV-1 VLPs
(Shioda and Shibuta, 1990). The p41 intermediate was
observed only in fractions at the top of the gradient. The
release of this p41 protein in a soluble form into culture
media may help explain why relatively little particulate
FIG. 3. Autoradiographs indicating that released HIV-1 Gag and SIV MA proteins, but not released HIV-1 MA alone, penetrated into sucrose density
gradients. (A) H9 cells were infected with V V:gag (HIV-1), starved, and labeled with 3H-leucine overnight. The medium was filtered, layered over a
sucrose density gradient, and ultracentrifuged for 3 h at 125,000 g. (B) H9 cells were infected with rV Vmatrix (HIV-1), starved, and labeled with
3H-leucine overnight. The medium was filtered, layered over a sucrose density gradient, and ultracentrifuged for 3 h at 125,000 rpm. (C) CV-1 cells
were infected with rV Vp17 (SIV), starved and labeled with 3H-leucine overnight. The medium was filtered, layered over a sucrose density gradient,
and ultracentrifuged for 3 h at 125,000 g.
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Gag protein was observed in fractions 8–12, despite high
levels of Gag expression in the cells (e.g., Fig. 1). Inter-
estingly, HIV-1 MA expressed by rVVmatrix (HIV-1), un-
like the MA and CA proteins from VV:gag (HIV-1) in H9
cells, remained mostly among the soluble proteins at the
top of the gradient in fractions 1–3 (Fig. 3b). A small
amount of HIV-1 MA protein penetrated all the way
through the gradient into fraction 17, most likely the result
of nonspecific aggregation or MA associated with filter-
able cell fragments. Similar results were obtained with
VV:gag (HIV-1) or rV Vmatrix (HIV-1) infections of CV-1
cells (not shown).
MA expressed by rV Vp17 (SIV) in CV-1 cells, as ex-
pected based on the previous work in CV-1 cells of
Gonzalez et al. (1993) migrated into the sucrose gradient
(Fig. 3c). The 17-kDa bands localized to fractions 9–11,
the average density of which was 1.12 g/ml. Low-density
VLPs have also been reported following expression of
mutant HIV-1 gag genes that lacked the I domain (San-
defur et al., 1998). These sucrose gradient results indi-
cated that while recombinant HIV-1 Gag or SIV MA
formed VLPs, recombinant HIV-1 MA alone did not form
VLPs in either H9 or CV-1 cells. However, it remained
possible that aberrant membrane-bound particles
formed by HIV-1 MA might be of insufficient density to
penetrate the gradient or that the protein in fraction 17
was due to aggregated particles. It was also possible
that the apparent low-density VLPs of SIV MA were
protein aggregates or incompletely enveloped particles.
Expression of HIV-1 Gag, but not HIV-1 MA alone,
produced membrane-bound particles which were
trypsin resistant
To further investigate whether the proteins which were
expressed by rV Vmatrix (HIV-1), VV:gag (HIV-1), or
rVVp17 (SIV) assembled as membrane-bound particles,
we performed trypsin protection assays. After metabolic
labeling, the culture medium was clarified, filtered, and
divided into six aliquots. The first aliquot remained un-
treated, the second received trypsin inhibitor, the third
received triton X-100, the fourth received trypsin, the fifth
received trypsin and triton X-100, and the sixth received
trypsin and trypsin inhibitor. After an incubation period,
trypsin inhibitor was added, and the samples were lysed,
immunoprecipitated, and analyzed by SDS–PAGE. Tryp-
sin inhibitor alone, triton X-100 alone, or untreated sam-
ples served as controls. MA produced by VV:gag was
released into the media and had an approximate molec-
ular mass of 17 kDa: see lanes 1–3 under Gag-Pol (Fig.
4). After treatment of the VV:gag media with trypsin (lane
4), the MA protein still migrated at 17 kDa, indicating that
it had been protected from trypsin digestion by a lipid
bilayer. However, when trypsin and triton x-100 were
added together, so that lipid bilayers were disrupted by
the detergent, the 17-kDa protein was not observed and
a new cleavage product of lower molecular mass was
seen (lane 5). These results indicated that VV:gag re-
leased MA proteins as components of membrane bound
VLPs. It was also of interest that the Gag processing
intermediate, p41, was degraded by trypsin in the ab-
sence (lane 4) or presence (lane 5) of triton X-100, con-
firming the sucrose gradient data (Fig. 3a), which indi-
cated this protein was released in soluble form. This p41
proteolysis was specific to the activity of trypsin because
aliquots treated with trypsin inhibitor as well as trypsin
maintained the 41-kDa protein (lane 6). Interestingly, the
p24 CA protein, unlike MA, did not undergo proteolysis in
the presence of trypsin and triton X-100 (lane 5). This was
probably due to poor exposure of the single potential
dibasic trypsin cleavage site present in the CA of HIV-1
HXB2.
In contrast, the 17-kDa protein corresponding to HIV-1
FIG. 3—Continued
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MA in the culture medium of cells infected with rVVma-
trix (HIV-1) was cleaved following treatment with either
trypsin alone (lane 4, under MA-only) or trypsin plus
triton X-100 (lane 5). This HIV-1 MA protein remained
uncleaved in the control aliquots treated with trypsin
inhibitor alone (lane 3), triton X-100 alone (lane 2), or
untreated (lane 1). The protein remained uncleaved
when treated with trypsin inhibitor and trypsin (lane 6),
demonstrating that the digestion of HIV-1 MA was trypsin
specific.
When this assay was performed on the SIV MA ex-
pressed by rVVp17 (SIV), it was found that trypsin did not
cleave the MA protein even in the presence of detergent
(data not shown). This was probably due to SIV MA
protein folding, causing inaccessibility of the cleavage
sites to trypsin or to absence of one dibasic site which
was present in HIV-1. Therefore, trypsin was not useful
for assessing the membrane envelopment of the re-
leased SIV MA. When the experiment was repeated with
a different protease, useful data were obtained (see
below). The overall results from this set of experiments
provided strong evidence that the HIV-1 MA protein,
expressed in the absence of other HIV-1 proteins, was
unable to assemble and release VLPs.
Expression of SIV MA alone produced membrane-
bound particles which were resistant to proteinase K
To obtain definitive data on whether or not SIV MA
alone formed VLPs, we employed a different enzyme in
the protease protection assay. Since trypsin was not
useful, proteinase K and the protease inhibitor, phe-
nylmethylsulfonylfluoride (PMSF), were utilized. CV-1
cells were infected, labeled, and clarified. The filtered
medium was treated as follows: the first aliquot was
untreated, the second received PMSF, the third re-
ceived triton X-100, the fourth received proteinase K,
the fifth received proteinase K and triton X-100, and the
sixth received proteinase K and PMSF. After the incu-
bation period, PMSF was added and the samples were
lysed, immunoprecipitated, and analyzed by SDS–
PAGE. Medium from V V:gag (HIV-1) infected cells was
used as a positive control and results similar to those
for trypsin were obtained, except that CA in Aliquot 5
was digested by proteinase K, which cleaves peptide
bonds with much less specificity than does trypsin
(data not shown). SIV MA produced by rV Vp17 (SIV)
was released into the media and had an approximate
molecular mass of 16–17 kDa (lanes 1–4 and lane 6,
Fig. 5). After treatment with proteinase K (lane 4), the
SIV MA protein of 16–17 kDa was still present, indi-
cating that it was protected from proteinase K diges-
tion by a lipid bilayer. However, when proteinase K and
triton X-100 were added together, disrupting the lipid
layer bilayer, the 16–17 kDa protein disappeared (lane
5). These results indicated that rV Vp17 (SIV)-infected
cells released SIV MA proteins as components of
membrane bound particles, thereby confirming that
SIV MA can form VLPs.
FIG. 4. Trypsin protection assays indicating HIV-1 Gag, but not HIV-1 MA alone, assembled into lipid bound particles. H9 cells infected with rV Vs
were labeled with 3H-leucine overnight. The medium were filtered and split into six aliquots. Reagents were added to each aliquot as follows: Aliquot
1, untreated; Aliquot 2, trypsin inhibitor at a 500 mg/ml final concentration; Aliquot 3, triton x-100 to 1%; Aliquot 4, trypsin at a 200 mg/ml final
concentration; Aliquot 5, triton x-100 to 1% and 200 mg/ml trypsin; and Aliquot 6, 200 mg/ml trypsin and 500 mg/ml trypsin inhibitor. After 30 min, trypsin
inhibitor was added to the tubes that had not received it to stop reactions. The media fractions were immunoprecipitated followed by SDS–PAGE and
autoradiography.
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DISCUSSION
As demonstrated above by metabolic labeling, density
gradient centrifugation, and protease protection, recom-
binant expression of HIV-1 gag-pol resulted in Gag syn-
thesis with posttranslational modification, polyprotein
processing, and production of membrane bound VLPs of
appropriate density. Similarly, recombinant expression of
HIV-1 MA alone in the absence of other HIV-1 proteins
resulted in a 17-kDa immunoreactive protein that was
released into the culture medium, pelleted through a 20%
sucrose cushion, and was posttranslationally modified
with myristic acid. These results initially suggested that
the HIV-1 MA alone might be sufficient for the assembly
and release of VLPs, as had previously been described
for SIVsmm (Gonzalez et al., 1993; Liska et al., 1994).
However, when the culture medium from cells express-
ing HIV-1 MA alone was layered over a sucrose density
gradient, most of the MA protein failed to enter into the
gradient. These data were consistent with two interpre-
tations: (1) the released HIV-1 MA protein was in soluble
form and so failed to penetrate the gradient or (2) the
HIV-1 MA protein was released within aberrant mem-
brane bound VLPs possessing insufficient density to
enter the gradient. The small amount of HIV-1 MA which
pelleted completely through the 20–60% density gradient
was likely an artifact; i.e., an aggregation of soluble MA
protein or VLPs or MA protein associated with lysed
cellular fragments.
To permit direct comparison of our HIV-1 MA results
with SIV MA, recombinant expression of SIV MA alone
was also performed utilizing these systems, and resulted
in an immunoreactive protein of 16–17 kDa that was
released into the culture medium and pelleted through a
sucrose cushion. The density gradient analysis of culture
medium obtained from cells expressing SIV MA alone
revealed that this 16–17 kDa immunoreactive protein
migrated into the gradient to a density of 1.12 g/ml.
To determine which of the possible interpretations
cited above for the HIV-1 MA data were correct, a trypsin
protection assay was utilized. In this experiment, MA and
CA released into the medium of cells expressing the
complete HIV-1 gag and pol genes were protected
against trypsin digestion, indicating Gag has assembled
into particles surrounded by a lipid bilayer. In contrast,
the HIV-1 MA protein expressed alone and released into
cell culture medium was susceptible to trypsin digestion
even in the absence of detergent and therefore was not
present in membrane bound particles. Taken together
with the density gradient results, these trypsin protection
data clearly indicated that HIV-1 MA protein alone was
incapable of assembling into VLPs.
This conclusion for HIV-1 MA differed from two previ-
ous reports which also employed vaccinia expression
but indicated that SIVsmm MA was sufficient for the as-
sembly and release of VLPs (Gonzalez et al., 1993; Liska
et al., 1994). The SIV MA density gradient data that we
obtained appeared to confirm those results. To be cer-
tain, the trypsin protection assay was employed, but it
was discovered that trypsin did not cleave the SIV MA
particles even in the presence of detergent. Therefore,
proteinase K was utilized in the protection assay, and it
was observed that the SIV MA VLPs were protected from
proteolysis unless detergent was added. Thus SIV MA
alone was capable of forming low density VLPs in the
absence of other viral proteins.
Why was HIV-1 MA incapable of assembly into VLPs
while SIV MA was capable of forming particles? One
possibility is that the assembly requirements for HIV-1
MA differ from those for SIV MA. Several residues that
were shown to be important for the proper folding of
SIVmac MA are altered in HIV-1 (Rao et al., 1995). These
include the glycine-45 and alanine-47 of SIV MA which
may be involved in the hydrogen bonding responsible
for trimerization of MA. In HIV-1 MA, these residues
are alanine-45 and asparagine-47, respectively. HIV-1
MA also has one less cysteine and methionine than
SIV MA, which might also affect its conformation and
make it less likely to form tight self-associations. The
HIV-1 and SIVsmm MA proteins also have very little
sequence similarity in their C-terminal regions, and
FIG. 5. Proteinase K protection assay indicating SIV MA assembled
into lipid bound particles. CV-1 cells infected with rV Vp17 (SIV) were
labeled with 3H-leucine for 4 h, fresh medium was added, and labelling
was continued overnight. The medium was filtered and split into six
aliquots. Reagents were added to each aliquot as follows: Aliquot 1,
untreated; Aliquot 2, PMSF at a 2.5 mg/ml final concentration; Aliquot 3,
triton X-100 to 1%; Aliquot 4, proteinase K at 10 mg/ml final concentra-
tion; Aliquot 5, triton X-100 to 1% and 10 mg/ml proteinase K; Aliquot 6,
10 mg/ml proteinase K and 2.5 mg/ml PMSF. After 1 h at 37°C, PMSF
was added to the tubes that had not received it to stop reactions. The
media fractions were immunoprecipitated followed by SDS–PAGE and
autoradiography.
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this region could play a role in the self assembly of
these proteins.
Interestingly, it was shown by deleting the entire MA
coding sequence that MA may be dispensable for
particle formation by HIV-1 Gag (Franke et al., 1994;
Lee and Linial, 1994). However, smaller mutations
within HIV-1 MA disrupted particle formation (Freed et
al., 1994; Wagner et al., 1994; Chazal et al., 1995). Small
mutations in SIV MA which could possibly change its
conformation were also shown to abolish particle for-
mation in the context of Gag (Gonzalez et al., 1996). It
appears that the contributions of MA to particle as-
sembly depend on MA conformation. SIVsmm MA may
assemble without the aid of the other Gag components
because its conformation permits more efficient self-
association than occurs with HIV-1 MA. Despite the
fact that in some systems the Gag proteins of HIV-1
and SIV may bind together (Franke et al., 1994), the
requirements for their MA association and assembly
appear to be different. Our results with HIV-1 and SIV
clearly indicate that self-assembly of MA into VLPs is
not a general feature of the primate lentiviruses.
MATERIALS AND METHODS
Cells and viruses
The human T-cell lymphoma cell line, H9, was main-
tained in RPMI supplemented with 12% fetal bovine
serum (FBS). The simian cell line, CV-1, was main-
tained in DMEM supplemented with 12% FBS. The
recombinant vaccinia virus (rV V) constructs utilized
were V V:gag (provided by the NIH AIDS repository,
catalog No. 405, contributed by Edgar Engleman), rV-
Vmatrix (HIV-1) (provided by Connie Bergman, USC),
rV Vp17 (SIVsmm) (provided by Silvia Gonzalez; desig-
nated v-p17gag in Gonzalez et al., 1993), and rVV/SC11,
a control recombinant which expresses the lacZ gene
(Owens and Compans,1989). The cloning strategy for
V V:gag was described (Gowda et al., 1989). This con-
struct expresses the Gag and Pol proteins of HIV-1
HXB2. rV Vmatrix (HIV-1) was created using PCR am-
plification from the cDNA for the HXB2 strain of HIV-1
using the following primers: 59-59-CTCTGCGCTAGC-
CGCCATGGGTGCGAGAGCGTC; and 39-59-CGGGGCC-
TCGAGACTAGTTAATTAGTAATTTTGGCTGAC. This strat-
egy results in a stop codon being placed directly after
the codon for the last amino acid of MA, the p17/p24
cleavage site. The PCR products were cut with NcoI/
SpeI and inserted into the pK vector, a previously
described derivative of the pSC11 plasmid (Bergman
et al., 1993). The recombinant virus was constructed
through homologous recombination using the WR
strain of vaccinia (Connie Bergman, personal commu-
nication). This construct expresses HIV-1 MA in the
absence of other HIV-1 proteins. The cloning strategy
for the rV Vp17(SIV) has been described (Gonzalez et
al., 1993). This construct expresses SIVsmm MA in the
absence of other SIV viral proteins. Stocks of the
vaccinia viruses were grown in either TK- or BHK-21
cell lines maintained in DMEM supplemented with
12% FBS. These stocks were titered in CV-1 cells.
Protein expression, labeling, and immunoprecipitation
H9 cells were infected with the HIV-1 or control rV Vs
in serum-free RPMI at a multiplicity of infection (m.o.i.)
of 8 plaque-forming units (pfu)/cell. After 2 h the media
was removed after a low-speed centrifugation and the
cells were incubated for 30 min in leucine-free Eagle’s
medium. Cultures were then labeled for 4 h with 200
mCi/ml 3H-leucine in Eagle’s medium. Fresh leucine-
free media and RPMI supplemented with 12% FBS
(complete media) were added at a ratio of 3:1, and
labeling was continued overnight. The final concentra-
tion of complete media was 20%. CV-1 cells were
infected with HIV-1 Gag, HIV-1 MA, SIV MA, or control
rV Vs in serum free DMEM at a m.o.i. of 8 and treated
as above. All incubations were done at 37°C. Alterna-
tively, H9 cells in RPMI were infected with the HIV-1 or
control rV Vs at an m.o.i. of 5 for 2 h, then washed and
labeled overnight with 3H-myristic acid. The media
from these cultures was then layered over a 20%
sucrose cushion and centrifuged in an ultracentrifuge
(Beckman Instruments, Inc., Palo Alto, CA) using an
SW41 ti rotor (Beckman Instruments) at 125,000 g for
3 h to pellet virus-like particles. The pellets were
resuspended in lysis buffer (1% triton X-100, 1% so-
dium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl pH
7.5, 10 mM EDTA). The cells were subjected to low-
speed centrifugation and lysed with lysis buffer. HIV-1
or SIV proteins in media, pellets, or cell lysate super-
natants were immunoprecipitated overnight at 4°C
with rotation using protein A-agarose beads and
pooled sera from HIV-1 infected patients or SIV in-
fected monkeys. The beads were collected by low-
speed centrifugation, washed twice with lysis buffer,
and boiled for 10 min in reducing buffer (2% SDS, 10%
glycerol, 5% 2-mercaptoethanol, 50 mM Tris-HCl pH
6.8, 0.1% bromphenol blue). The proteins were sepa-
rated on 11.5 or 15% SDS–PAGE gels and visualized by
autoradiography.
Density gradient centrifugation
Culture media from infected H9 or CV-1 cells were
clarified by low-speed centrifugation for 5 min and fil-
tered through 0.45-mm filters. The clarified media were
layered over 20–60% linear sucrose gradients and cen-
trifuged at 125,000 g for 3 h using an SW41 ti rotor.
Gradient fractions were collected from the top and di-
luted with lysis buffer. Density measurements with a
refractometer (Bausch & Lomb) were taken before dilu-
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tion. The samples were then immunoprecipitated and
analyzed as above.
Protease protection assay
Cultures of 5 3 106 H9 or CV1 cells were infected
with V V:gag (HIV-1), rV Vmatrix (HIV-1), rV Vp17 (SIV), or
the control rV V at an m.o.i. of 8 and labeled as above.
After the overnight labeling period, the cells were
collected and treated as above with lysis buffer. The
culture media were filtered, and each was divided into
six equal aliquots and treated following a method
previously described (Wills et al., 1989). The first ali-
quot received no further treatment. The second aliquot
received soybean trypsin inhibitor (Sigma, Inc., St.
Louis, MO) to a final concentration of 500 mg/ml or 2.5
mg/ml PMSF (Sigma). The third aliquot received triton
x-100 to 1%. The fourth aliquot received trypsin to a
final concentration of 200 mg/ml or proteinase K to a
final concentration of 10 mg/ml. The fifth aliquot re-
ceived both triton X-100 to 1% and trypsin (200 mg/ml)
or proteinase K (10 mg/ml). The sixth aliquot received
trypsin (200 mg/ml) and an excess of trypsin inhibitor
(500 mg/ml) or proteinase K (10 mg/ml) and an excess
of PMSF (2.5 mg/ml). The trypsin samples were then
incubated at room temperature for 30 min, after which
trypsin inhibitor was added to all samples that did not
previously receive it. The proteinase K samples were
incubated at 37°C for 1 h, after which PMSF was
added to all samples that did not previously receive it.
Lysis buffer or 5x was added to all samples, followed
by immunoprecipitation, SDS–PAGE, and autoradiog-
raphy as above.
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